CUMBERLAND PHARMACEUTICALS INC
For the period ended Mar 4, 2025. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 4, 2025 · Filed Mar 4, 2025
Contents
EX-99.1 · Clinical Development Programs
Clinical Development Programs
Throughout 2024, Cumberland made significant progress in advancing the Phase II clinical trials evaluating its ifetroban product candidate. The Company closed its study in patients with Duchenne muscular dystrophy, approached the conclusion of enrollment in its systemic sclerosis study and significantly progressed its study in patients suffering from pulmonary fibrosis. These programs are designed to address unmet medical needs in large potential markets.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.